6月25日,阿斯利康中国宣布了一项重大战略举措:为进一步推动战略转型与管线加速,自2025年7月1日起,公司将正式启动新一轮组织架构优化,重磅设立消化道肿瘤事业部(GI BU)与早期管线业务部(Early Assets Unit)两大全新业务板块。消化道肿瘤事业部:该事业部致力于布局胆道癌、肝癌、食管癌、结直肠癌、胃癌、胰腺癌等多种消化道肿瘤的创新药物和联合治疗方案。任命现肺癌事业部中央市场部...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.